What do we know about Chinese COVID-19 vaccines? Efficiency below 80 percent.

In China, five domestic-produced vaccines have already been approved for use. Some of them are also used in other countries. What do we know about their effectiveness? Which one seems to be the best?

1. Four vaccines are currently approved for use in Poland: Pfizer, Moderny, AstraZeneki and Johnson & Johnson
2. For now, there are no plans to use preparations from China in our country
3. Chinese vaccines are used, inter alia, in Hungary, Chile or Mexico
4. You can find more such stories on the TvoiLokony home page

Chinese COVID-19 vaccines – which have been approved?

Sinopharm is a state-owned company that is working on two different vaccines. The first was developed at the Sinopharm institute in Beijing and the second in Wuhan, but both are based on an inactivated form of SARS-CoV-2. The third vaccine available, called CoronaVac, was developed by the Beijing-based pharmaceutical company Sinovac. It is also based on the inactivated form of SARS-CoV-2. All three require two doses. In contrast, the vaccine developed by CanSinoBIO consists of only a single dose and uses the human Ad5 adenovirus to deliver SARS-CoV-2 proteins into the body (similar to the Sputnik-V vaccine, which also uses Ad5, as well as another adenovirus).

1. See also: Doctors are arguing over amantadine. And they heal with it when they get sick

Previously, CanSinoBIO used the same approach to develop an Ebola vaccine that was approved for emergency use in China. Pharmaceutical company Anhui Zhifei Longcom’s fifth vaccine candidate received emergency approval on March 16. This vaccine, in turn, requires three doses and uses proteins based on the SARS-CoV-2 receptor binding domain. All five vaccines can be stored at standard temperatures.

Chinese COVID-19 vaccines are already being used in these countries

The first Sinopharm vaccine has received the most emergency approvals to date, in nearly 30 countries, including Bahrain, Guyana, Hungary, Serbia and the United Arab Emirates. Hungary was the first EU country to approve the use of a Chinese vaccine, and Prime Minister Viktor Orbán was one of those to receive it. Several countries have approved Sinovac CoronaVac for emergency use, including Brazil, Chile (where the vaccine has been tested), Indonesia, Laos, Mexico, and Turkey. Mexico and Pakistan have approved the use of the CanSinoBIO vaccine, and the Anhui Zhifei Longcom vaccine has been approved for use in Uzbekistan.

Chinese vaccines against COVID-19 – clinical trials

The results of the phase I and II studies for CoronaVac in two age groups: 18-59 and 60+ were published in the Lancet on November 2 and February 3. The studies found immunogenicity in the majority of patients and that the vaccine was generally safe and well tolerated, with few side effects. Phase I and II data for Anhui Zhifei Longcom, released on March 4, showed similar results. So far, no Phase III trial data for any of the Chinese vaccine candidates has been published in a peer-reviewed journal. CanSinoBIO said it intended to do so, but did not provide any timeframe.

1. Editors recommend: Thrombosis and thrombocytopenia after COVID-19 vaccine. Where do they come from?

Most of what we know comes from the announcements made by the manufacturers and governments of the countries where the tests are being carried out. Sinopharm said in December that his first vaccine was 79% effective. in the prevention of symptomatic COVID-19, based on interim phase III data. That’s less than 86 percent. efficacy reported earlier in the same month by the United Arab Emirates, where the vaccine was also tested. Other countries testing this vaccine are Bahrain, Egypt, Jordan and Peru. Sinopharm also said his second vaccine, from the Wuhan Institute, proved slightly less effective at 72,5 percent.

Also in December, Turkish officials released provisional survey data showing Sinovac’s CoronaVac was 91,25 percent. effective in preventing symptomatic COVID-19 in a subgroup of 1322 participants. However, in January, Brazilian scientists announced that the CoronaVac vaccine was 78% effective. in the prevention of mild cases, according to data from a Phase III study of 12 healthcare professionals in this country. Just a week later, additional data emerged, including very mild cases, and suggesting that the vaccine was only 000% effective. against symptomatic COVID-50,4. In the same month, Indonesian authorities said the vaccine was 19 percent effective.

A single administration of CanSinoBIO turned out to be 75 percent. effective in a study conducted in Pakistan. The vaccine is also being tested in Argentina, Chile, Mexico and Our Country.

Source: Medexpress, author: Magda Mazurek

Also read:

1. You don’t have to disinfect everything? Experts change recommendations
2. Experts: we will win with the pandemic if 60 percent. the population will wear masks and keep their distance
3. Grzesiowski: «drive thru» vaccination points break safety rules. Vaccination is not fast food
4. Will there be consequences for people not getting the COVID-19 vaccine?
5. How many people in Poland died or had thrombosis after vaccination? New data
6. Will it also be possible to mix COVID-19 vaccines in Poland? The Ministry of Health responds

The content of the medTvoiLokony website is intended to improve, not replace, the contact between the Website User and their doctor. The website is intended for informational and educational purposes only. Before following the specialist knowledge, in particular medical advice, contained on our Website, you must consult a doctor. The Administrator does not bear any consequences resulting from the use of information contained on the Website. Do you need a medical consultation or an e-prescription? Go to halodoctor.pl, where you will get online help – quickly, safely and without leaving your home.Now you can use e-consultation also free of charge under the National Health Fund.